Novartis has its blockbuster Beovu OK, but its 'hot mess' label leaves something to be desired: analysts

10th October 2019 Uncategorised 0

Novartis this week won FDA approval for Beovu, a wet AMD med that’s expected to become a blockbuster. But the drug will be going up against entrenched rivals with some blemishes in its label, analysts wrote. The label doesn’t specifically describe dosing schedules, and the new drug carries inflammation risks.

More: Novartis has its blockbuster Beovu OK, but its 'hot mess' label leaves something to be desired: analysts
Source: fierce